Pretomanid is being analyzed as Section of a combination regimen like moxifloxacin and PZA to the treatment of both drug-susceptible and drug-resistant tuberculosis (ClinicalTrials.gov identifier: NCT02193776). Bedaquiline, permitted through the US FDA for treatment of multidrug-resistant tuberculosis in 2012, can be being investigated in drug-incl